This site is intended for healthcare professionals
Latest drug news
  • Home
  • /
  • News
  • /
  • 2024
  • /
  • 7
  • /
  • PARI Pharma GmbH announces termination of ColiFin ...

PARI Pharma GmbH announces termination of ColiFin license to EnBiotix, Inc./Spexis AG

Read time: 1 mins
Published:9th Jul 2024

Spexis AG announced that PARI Pharma GmbH the owner of ColiFin, its combination drug-device inhaled colistin product, has terminated the license of ColiFin to EnBiotix, Inc., the wholly-owned subsidiary to which ColiFin® was licensed in 2019

PARI terminated the license pursuant to non-payment of a required license payment by Enbiotix, Inc. to PARI.

The shares and assets of Enbiotix and Spexis’ other wholly-owned subsidiary Spexis Australia Pty Ltd were both subject to a receivership which SPRIM implemented as part of its alleged default of certain conditions of loans extended to Spexis, which Spexis maintains it did not breach. As a result of this non-payment and resulting license termination, Spexis is continuing its negotiations with SPRIM regarding debt-restructuring while it weighs its further business and legal options aimed in the short term to obtain a definitive moratorium at the upcoming court hearing scheduled for 23 July 2024. In parallel, Spexis will seek to re-in-license ColiFin from PARI directly, subject to the Company completing a debt-restructuring with its creditors and obtaining sufficient additional financing, which the Company aims to raise in its ongoing and multi-pronged fundraising and strategic transaction campaign to ultimately exit from moratorium. There can be no assurance that such efforts will be successful.

Jeff Wager, MD, Chairman & CEO of Spexis, said: “This license termination is obviously unfortunate in light of present moratorium circumstances, but we are committed as a Company to fully explore all avenues available to re-acquire rights to ColiFin®, continue debt-restructuring with our creditors in the framework of a definitive moratorium in the immediate term and ultimately exit from moratorium. There is increasing interest in macrocycles, next-generation alternatives to antibody-drug-conjugates and also radio-pharmaceuticals, and these are all areas in which Spexis has proven assets and a unique product pipeline. We will continue to vigorously market these assets and opportunities as part of its fundraising and transaction campaign to firstly, obtain a definitive moratorium and then, continue to seek to exit moratorium and ultimately, to deliver superior returns to shareholders.”

Condition: Cystic Fibrosis/Pseudomonas aeruginosa
Type: drug

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

Related news and insights